Atara Biotherapeutics vs CG Oncology
Atara Biotherapeutics is the larger business, with $121m of revenue in fiscal 2025 against $4.0m for CG Oncology (29.9 times as much). CG Oncology grew faster (254.7% against -6.3%). Atara Biotherapeutics kept more of each dollar of sales as profit: a net margin of 27.1% against -3985.0%.
| Latest fiscal year | Atara BiotherapeuticsATRA, 2025 | CG OncologyCGON, 2025 |
|---|---|---|
| Revenue | $121m | $4.0m |
| Revenue growth | -6.3% | 254.7% |
| Net income | $32.7m | −$161m |
| Operating margin | 29.7% | -4722.1% |
| Net margin | 27.1% | -3985.0% |
| Return on equity | — | -21.7% |
| Free cash flow | −$50.9m | −$132m |
| Cash | $8.5m | $32.5m |
| Total debt | $0 | $3.0m |
| Debt to equity | — | 0.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | 142 |
| Market value | $80.1m | $5.47bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 2 buys, 18 sales | 1 buys, 17 sales |